Osteomyelitis is an infectious process in bone that occasionally leads to bone destruction. Traditionally, the surgical treatment procedure is performed in combination with systemic and local antibiotics as a two-stage procedure that uses autograft or allograft bone for filling of the cavitary defect. Bioactive glass (BAG-S53P4) is a bone substitute with proven antibacterial and bone bonding properties.
One hundred and sixteen patients who had verified chronic osteomyelitis was treated using BAG-S53P4 as part of the treatment. Most of the patients had previously undergone numerous procedures, sometimes for decades. A register of patient data obtained from 11 centers from Finland, Italy, the Netherlands, Germany, Azerbaijan and Poland was set-up and continuously maintained at Helsinki University Central Hospital.
The location of the osteomyelitis was mainly in the tibia followed by the femur and then the calcaneus. The median age of the patients was 48 years (15–87). The patients were either treated according to a one-stage procedure without local antibiotics (85 %) or by a two-stage procedure using antibiotic beads in the first procedure (15 %). The minimum follow-up was 1 year (12–95 months, median 31).
The cure rate was 104/116, the total success rate 90 % and most of the patients showed a rapid recovery.
The study shows that (BAG-S53P4) can be used in a one-stage procedure in treatment of osteomyelitis with excellent results.
Bioactive glass S53P4 Osteomyelitis Antibacterial Bone substitute
This is a preview of subscription content, log in to check access
We thank P Venesmaa, Kuopio University Hospital, Kuopio, Finland, M Nyyssönen, North Karelia Central Hospital, Joensuu, Finland, M Kirjavainen Helsinki University Central Hospital, Helsinki, Finland, and E Gullichsen, Turku University Hospital, Turku, Finland for their contributions of cases.
Cierny G 3rd, Mader JT, Pennick JJ (2003) A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res 414:7–24CrossRefGoogle Scholar
Coraca-Huber D, Fille M, Hausdorfer J, Putzer D, Nogler M (2014) Efficacy of antibacterial bioactive glass S53P4 against S. aureus biofilms grown on titanium discs in vitro. J Orthop Res 32:175–177CrossRefPubMedGoogle Scholar
Drago L, Romano D, De Vecchi E, Vassena C, Logoluso N, Mattina R, Romano CL (2013) Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bone: an in vitro and prospective clinical study. BMC Infect Dis 10:584. doi:10.1186/1471-2334-13-584CrossRefGoogle Scholar
Drago L, Vassena C, Fenu S, De Vecchi E, Signori V, De Francesco R, Romano CL (2014) In vitro antibiofilm activity of bioactive glass S53P4. Future Microbiol 9:593–601CrossRefPubMedGoogle Scholar
Drago L, De Vecchi E, Bortolin M, Toscano M, mattina R, Romano CL (2015) Antimicrobila activity and resistance selection of different bioglass S53P4 formulations against multidrug resistance strains. Future Microbiol 10:1293–1299CrossRefPubMedGoogle Scholar
Frantzén J, Rantakokko J, Aro H, Heinänen J, Kajander S, Koski I, Gullichsen E, Kotilainen E, Lindfors N (2011) Instrumented spondylodesis in degenerative spondylolisthesis with bioactive glass and autologous bone. A prospective 11-year follow-up. J Spinal Disorder Tech 24(7):455–461CrossRefGoogle Scholar
Heikkilä JT, Kukkonen J, Aho AJ, Moisander S, Kyyrönen T, Mattila K (2011) Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral tibial plateau fractures: a prospective, randomized 1 year follow-up study. J Mater Sci Mater Med 22(4):1073–1080CrossRefPubMedGoogle Scholar
Lazzarini L, Lipsky BA, Mader JT (2005) Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Inf Dis 9:127–138CrossRefGoogle Scholar
Lindfors NC, Heikkilä J, Koski I, Mattila K, Aho AJ (2009) Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res 90B(1):131–136CrossRefGoogle Scholar
Lindfors NC, Koski I, Heikkilä JT, Mattila K, Aho AJ (2010a) A prospective randomized 14-year follow-up study of bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors. J Biomed Mater Res 94B(1):157–164Google Scholar
Lindfors NC, Hyvönen P, Nyyssönen M, Kirjavainen M, Kankare J, Gullichsen E, Salo J (2010b) Bioactive glass S53P4 as bone graft substitute in treatment of osteomyelitis. Bone 47:212–218CrossRefPubMedGoogle Scholar
Leppäranta O, Vaahtio M, Peltola R, Ziang D, Hupa L, Hupa M, Ylänen H, Salonen JI, Viljanen MK, Eerola E (2008) Antibacterial effect of bioactive glasses on clinically important anaerobic bacteria in vitro. J Mater Sci Mater Med 19:547–551CrossRefPubMedGoogle Scholar
McPherson EJ, Woodson C, Holtom O, Roidis N, Shufelt C, Patzakis M (2003) Periprosthetic total hip infection. Outcome using a staging system. Vlin Orthop Relat Res 403:8–15CrossRefGoogle Scholar
Munukka E, Leppäranta O, Korkeamäki M, Vaahto M, Peltola T, Zhang D, Hupa L, Ylänen H, salonen JI, Virtanen MK, Eerola E (2008) Bacterial effects of bioactive glasses on clinically important aerobic bacteria. J Mater Sci Mater Med 19:27–32CrossRefPubMedGoogle Scholar
Peltola M, Aitasalo K, Suonpaa J, Varpula M, Yli-Urpo A (2006) Bioactive glass S53P4 in frontal sinus obliteration: A long-term clinical experience. Head Neck 28(9):834–841CrossRefPubMedGoogle Scholar
Pernaa K, Koski I, Mattila K, Gullichsen E, Heikkilä J, Aho AJ, Lindfors N (2011) Bioactive glass S53P4 and autograft bone in treatment of depressed tibial plateau fractures. A prospective randomized 11-year follow-up. J Long Term Eff Med Impl 21(2): 139–148CrossRefGoogle Scholar
Rantakokko J, Frantzén J, Heinänen J, Kajander S, Kotilainen E, Gullichsen E, Lindfors N (2012) Posterolateral spondylodesis using bioactive glass S53P4 and autogenous bone in instrumented unstable lumbar spine burst fractures – a prospective 10-year follow-up study. Scand J Surg 101:66–71CrossRefPubMedGoogle Scholar
Romano CL, Logoluso N, Meani E, Romano D, De Vecchi E, Vassena C, Drago L (2014) A comparative study of the use of bioactive glass S53P4 and antibiotic-loaded calcium-based bone substitutes in the treatment of chronic osteomyelitis. Bone Joint J 96-B:845–850CrossRefPubMedGoogle Scholar
Sarin J, Grenman R, Aitasalo K, Pulkkinen J (2012) Bioactive glass S53P4 in mastoid obliteration surgery for chronic otitis media and cerebrospinal fluid leakage. Ann Otol Rhinol Laryngol 121:563–569CrossRefPubMedGoogle Scholar
Silvola JT (2011) Mastoidectomy cavity obliteration with bioactive glass: a Pilot Study. Otolaryngol Head Neck Surg 145(2):P96–P97CrossRefGoogle Scholar
Stoor P, Mesimäki K, Lindqvist C, Kontio R (2015) The use of anatomically drop-shaped bioactive glass S53P4 implants in the reconstruction of orbital floor fractures-A prospective long-term follow-up study. J Craniomaxillofac Surg 43:969–975CrossRefPubMedGoogle Scholar
Virolainen P, Heikkilä J, Yli-Urpo A, Vuorio E, Aro HT (1997) Histomorphometric and molecular biologic comparison of bioactive glass granules and autogenous bone grafts in augmentation of bone defect healing. J Biomed Mater Res 35(1):9–17CrossRefPubMedGoogle Scholar
Välimäki VV, Aro HT (2006) Molecular basis for action of bioactive glasses as bone graft substitute. Scand J Surg 95(2):95–102CrossRefPubMedGoogle Scholar